ES304

ES304 is a bispecific immunotherapeutic candidate currently in the discovery or preclinical stage of development by Elpiscience Biopharmaceuticals. Designed for the treatment of autoimmune diseases, ES304 simultaneously targets Interleukin-10 (IL-10) and an undisclosed second target designated as 'Target-M.' The drug's mechanism of action is intended to restore immune homeostasis by leveraging the anti-inflammatory properties of IL-10 signaling while potentially engaging a complementary pathway via Target-M to enhance therapeutic efficacy or tissue specificity. By utilizing bispecific antibody engineering, ES304 aims to provide a targeted approach to suppressing excessive immune activation in various autoimmune conditions.